- LEO Pharma Canada and pCPA have successfully concluded negotiations for Anzupgo (delgocitinib cream), signing a Letter of Intent that advances public reimbursement for eligible adults with moderate to severe chronic hand eczema.
- Anzupgo is the first topical treatment specifically indicated for adults with moderate to severe CHE inadequately controlled with, or unsuitable for, topical corticosteroids, addressing a long-standing treatment gap.
- The treatment is supported by the Phase III DELTA program, while DELTA FORCE showed superior efficacy and a more favourable safety profile versus oral alitretinoin, the standard of care, over 24 weeks.
- The milestone follows a positive CDA-AMC reimbursement recommendation. LEO Pharma will now work with public drug plans and INESSS as listing decisions are considered across Canada.
Takeaways:
The pCPA Letter of Intent for Anzupgo (delgocitinib cream) moves Canada closer to public reimbursement for the first topical therapy specifically indicated for moderate to severe chronic hand eczema in adults who are not well controlled on, or not suitable for, topical corticosteroids. By offering a targeted topical option with evidence of superior efficacy and a better safety profile than oral alitretinoin in the DELTA FORCE trial, Anzupgo can shift some patients away from systemic therapy and expand the treatable population, strengthening LEO Pharma’s position in the Canadian dermatology market once provincial and INESSS listing decisions are finalized.
Source: Businesswire
